Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-03-01
2011-03-01
Chandrakumar, Nizal S (Department: 1625)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
active
07897770
ABSTRACT:
The present invention provides novel fluorinated ether compounds having structure Iwherein R1is a C2-C10fluorinated aliphatic radical; R2is a C1-C10aliphatic radical, or a C3-C10cycloaliphatic radical; R3is hydrogen or a C1-C10aliphatic radical; and R4is hydrogen or a C1-C10aliphatic radical. The fluorinated ether compounds are provided in both racemic and enantiomerically enriched forms and may comprise either or both of fluorine-18 and fluorine 19. The fluorinated ether compounds are shown to possess high affinity for VMAT-2, a biomarker implicated in human diabetes. The fluorinated ether compounds comprising a fluorine-18 group are useful as PET imaging agents targeting the VMAT-2 biomarker. The non-radiolabeled fluorinated ether compounds are useful as probes for the discovery of PET imaging agents.
REFERENCES:
patent: 2843591 (1958-07-01), Brossi et al.
patent: 4193998 (1980-03-01), Szantay et al.
patent: 5278308 (1994-01-01), Kung
patent: 1068261 (1959-11-01), None
patent: WO9316730 (1993-09-01), None
patent: WO 2005/077946 (2005-08-01), None
patent: WO2005077946 (2005-08-01), None
patent: WO2007005283 (2007-01-01), None
patent: WO2007130365 (2007-11-01), None
patent: WO2008154243 (2008-12-01), None
PCT International Search Report dated Apr. 3, 2009.
Zheng et al., “Computational Neural Network Analysis of the Affinity of Lobeline and Tetrabenazine Analogs for the Vesicular Monoamine Transporter-2”, Bioorganic & Medicinal Chemistry, vol. 15, pp. 2975-2992, 2007.
Popp et al., “Synthesis of Potential Antineoplastic Agents XXVI: 1,3,4,6,7,11b-Hexahydro-9,10-dimethoxy-2H-benso [a]2-quinolizinone Derivatives”, Journal of Pharmaceutical Sciences, vol. 67, No. 6, pp. 871-873, XP-002513807, Jun. 1978.
PCT International Search Report dated Feb. 18, 2009.
Kung et al., “Characterization of Optically Resolved 9-Fluoropropyl-Dihyrotetrabenzaine as a Potential PET Imaging Agent Targeting Vesicular Monoamine Transporters”, Nuclear Medicine and Biology, vol. 34, pp. 239-246, 2007.
Goswami et al., “Fluoroalkyl Derivatives of Dihydrotetrabenazine as Position Emission Tomography Imaging Agents Targeting Vesicular Monoamine Transporters”, Nuclear Medicine and Biology, vol. 33, pp. 685-694, 2006.
Kilbourn et al., “Pharmacokinetics of [18F]Fluoroalkyl Derivatives of Dihyrotetrabenazine in Rate and Monkey Brain”, Nuclear Medicine and Biology, vol. 34, pp. 233-237, 2007.
Amarasinghe Kande Kankanamalage Dayarathna
Dinn Sean Richard
Johnson Bruce Fletcher
Rishel Michael James
Caruso Andrew J.
Chandrakumar Nizal S
General Electric Company
LandOfFree
Fluorinated dihydrotetrabenazine ether imaging agents and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fluorinated dihydrotetrabenazine ether imaging agents and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fluorinated dihydrotetrabenazine ether imaging agents and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2655425